Section Arrow
ACAD.NASDAQ
- ACADIA Pharmaceuticals
Quotes are at least 15-min delayed:2025/11/04 07:40 EST
Pre Market
Last
 22.37
0 (0.00%)
Bid
21
Ask
22.2
High 22.37 
Low 22.37 
Volume
Regular Hours
Last
 22.37
-0.33 (-1.45%)
Day High 
22.78 
Prev. Close
22.7 
1-M High
23.045 
Volume 
1.82M 
Bid
21
Ask
22.2
Day Low
21.87 
Open
22.5 
1-M Low
19.69 
Market Cap 
3.83B 
Currency USD 
P/E 17.07 
%Yield -- 
10-SMA 22.09 
20-SMA 21.49 
50-SMA 23 
52-W High 26.6499 
52-W Low 13.4 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
1.33/1.12
Enterprise Value
3.87B
Balance Sheet
Book Value Per Share
4.87
Cash Flow
Cash Flow Yield
0.05
Income Statement
Total Revenue
957.80M
Operating Revenue Per Share
3.75
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
PHIOPhio Pharmaceuticals Corp1.86-0.19-9.27%0.01PE
Pre Market 1.69 -0.17 -9.14%
CRBUCaribou Biosciences2.43+0.01+0.41%-- 
Pre Market 2.42 -0.01 -0.41%
IOVAIovance Biotherapeutics1.95-0.02-1.02%-- 
Pre Market 1.91 -0.04 -2.05%
RXRXRecursion Pharmaceuticals5.44-0.08-1.45%-- 
Pre Market 5.25 -0.19 -3.49%
THARTharimmune Inc.3.2+0.25+8.47%0.03PE
Pre Market 3.01 -0.19 -5.94%
Quotes are at least 15-min delayed:2025/11/04 07:40 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.